Source 1primary paper2025MED
Toolkit/MHCK7
MHCK7
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Innovations in AAV engineering, such as capsid modification (chemical conjugation, rational design, directed evolution), self-complementary genomes, and tissue-specific promoters (e.g., MHCK7), enhance muscle tropism while mitigating immunogenicity and off-target effects.
Usefulness & Problems
Why this is useful
MHCK7 is presented as an example of a tissue-specific promoter used in AAV engineering for muscle-targeted delivery.; tissue-specific expression in muscle-targeted gene delivery; enhancing muscle tropism in AAV engineering
Source:
MHCK7 is presented as an example of a tissue-specific promoter used in AAV engineering for muscle-targeted delivery.
Source:
tissue-specific expression in muscle-targeted gene delivery
Source:
enhancing muscle tropism in AAV engineering
Problem solved
It is used to enhance muscle tropism and help mitigate off-target effects in targeted gene delivery.; improving muscle-targeted expression; mitigating off-target effects
Source:
It is used to enhance muscle tropism and help mitigate off-target effects in targeted gene delivery.
Source:
improving muscle-targeted expression
Source:
mitigating off-target effects
Problem links
improving muscle-targeted expression
LiteratureIt is used to enhance muscle tropism and help mitigate off-target effects in targeted gene delivery.
Source:
It is used to enhance muscle tropism and help mitigate off-target effects in targeted gene delivery.
mitigating off-target effects
LiteratureIt is used to enhance muscle tropism and help mitigate off-target effects in targeted gene delivery.
Source:
It is used to enhance muscle tropism and help mitigate off-target effects in targeted gene delivery.
Published Workflows
Objective: Enhance AAV9 vector functionality and phenotypic rescue in a murine DMD model by combining capsid engineering, promoter selection, and microdystrophin codon optimization.
Why it works: The paper states that combining rational AAV9 capsid engineering at post-translational modification sites with optimal promoter selection and codon-optimised microdystrophin was expected to enhance AAV9 vector functionality.
capsid modification at post-translational modification sitespromoter-driven enhancement of transgene expressioncodon optimization of microdystrophinrational capsid engineeringpromoter screeningin vivo intramuscular evaluationsystemic administration
Stages
- 1.Initial promoter screening(broad_screen)
This stage was used to identify the optimal promoter before downstream capsid and transgene optimization.
Selection: Improved dystrophin expression in muscle fibres
- 2.Engineered capsid intramuscular evaluation(functional_characterization)
This stage compared engineered AAV9 capsids in vivo after promoter selection to identify a better-performing capsid.
Selection: Improvement in grip strength after intramuscular delivery of CAG-μDys vectors
- 3.Optimized transgene plus selected promoter and capsid evaluation(secondary_characterization)
This stage tested whether adding codon optimization to the selected promoter and capsid further improved therapeutic performance.
Selection: Enhanced muscle grip strength and dystrophin-glycoprotein complex restoration with codon-optimised microdystrophin under CAG and AAV9K51Q
- 4.Systemic administration of selected optimized vector(in_vivo_validation)
This stage validated whether the best-performing intramuscular vector retained efficacy after systemic delivery.
Selection: Long-term improvement in muscle contraction force and dystrophin restoration in skeletal and cardiac muscles
Steps
- 1.Screen promoters for dystrophin expression in mdx mice
Identify the promoter that gives higher dystrophin expression in muscle fibres.
Promoter choice was evaluated first so that later capsid and transgene optimization could be performed in the best expression context.
- 2.Evaluate engineered AAV9 capsids carrying CAG-μDys by intramuscular deliveryengineered vectors under comparison
Compare engineered capsid variants in vivo after fixing the promoter choice.
Capsid testing followed promoter selection so capsid performance could be assessed using the selected expression cassette context.
- 3.Test codon-optimised microdystrophin with selected CAG promoter and AAV9K51Q capsid intramuscularlyoptimized vector configuration under validation
Determine whether codon optimization further improves the selected vector configuration.
Codon optimization was evaluated after promoter and capsid selection to test the combined optimized design in the best available vector context.
- 4.Advance the optimized AAV9K51Q vector to systemic administrationfinal selected therapeutic vector
Validate whether the optimized vector can deliver broad and durable therapeutic benefit after systemic dosing.
The abstract explicitly states that systemic administration was performed based on improved intramuscular performance of AAV9K51Q vectors.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
tissue-specific transcriptional controlTarget processes
No target processes tagged yet.
Input: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: actuator
The abstract supports MHCK7 as a promoter element within engineered AAV gene delivery systems.; used as a tissue-specific promoter component within engineered gene delivery constructs
Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
AAV-based therapies such as Elevidys for DMD and Zolgensma for SMA demonstrate functional improvements, although immune responses and hepatotoxicity remain concerns.
Clinically, AAV-based therapies (e.g., Elevidys® for DMD, Zolgensma® for SMA) demonstrate functional improvements, though immune responses and hepatotoxicity remain concerns.
Non-viral vectors including liposomes, polymers, and exosomes offer advantages in cargo capacity, biocompatibility, and scalable production, but they face challenges in transduction efficiency and endosomal escape.
Non-viral vectors (liposomes, polymers, exosomes) offer advantages in cargo capacity (delivering full-length dystrophin), biocompatibility, and scalable production but face challenges in transduction efficiency and endosomal escape.
AAV vectors dominate clinical applications for gene therapy in hereditary skeletal myopathies because they efficiently transduce post-mitotic myofibers and support sustained transgene expression.
Adeno-associated virus (AAV) vectors dominate clinical applications due to their efficient transduction of post-mitotic myofibers and sustained transgene expression.
AAV engineering innovations including capsid modification, self-complementary genomes, and tissue-specific promoters such as MHCK7 enhance muscle tropism while mitigating immunogenicity and off-target effects.
Innovations in AAV engineering, such as capsid modification (chemical conjugation, rational design, directed evolution), self-complementary genomes, and tissue-specific promoters (e.g., MHCK7), enhance muscle tropism while mitigating immunogenicity and off-target effects.
Future targeted gene delivery strategies for muscular disorders emphasize AI-driven vector design, AAV-exosome hybrid systems, and standardized manufacturing to pursue single-dose lifelong therapeutic benefit.
Future directions focus on AI-driven vector design, hybrid systems (AAV-exosomes), and standardized manufacturing to achieve "single-dose, lifelong cure" paradigms for muscular disorders.
Approval Evidence
1 source1 linked approval claimfirst-pass slug mhck7
Innovations in AAV engineering, such as capsid modification (chemical conjugation, rational design, directed evolution), self-complementary genomes, and tissue-specific promoters (e.g., MHCK7), enhance muscle tropism while mitigating immunogenicity and off-target effects.
Source:
engineering effectsupports
AAV engineering innovations including capsid modification, self-complementary genomes, and tissue-specific promoters such as MHCK7 enhance muscle tropism while mitigating immunogenicity and off-target effects.
Innovations in AAV engineering, such as capsid modification (chemical conjugation, rational design, directed evolution), self-complementary genomes, and tissue-specific promoters (e.g., MHCK7), enhance muscle tropism while mitigating immunogenicity and off-target effects.
Source:
Comparisons
Source-backed strengths
presented as a tissue-specific promoter example in muscle-targeted AAV engineering
Source:
presented as a tissue-specific promoter example in muscle-targeted AAV engineering
Compared with bacterial degrons
MHCK7 and bacterial degrons address a similar problem space.
Shared frame: same top-level item type; same primary input modality: chemical
MHCK7 and Pyr-NHS-functionalised 3D graphene foam electrode biosensor address a similar problem space.
Shared frame: same top-level item type; same primary input modality: chemical
Compared with rM3Ds
MHCK7 and rM3Ds address a similar problem space.
Shared frame: same top-level item type; same primary input modality: chemical
Ranked Citations
- 1.